
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options with no options contract fees
- Get up to $1,000 in stock when you open and fund a new account within 30 days
- Access to a financial planner
Adverum Biotechnologies is a biotechnology business based in the US. Adverum Biotechnologies shares (ADVM) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.49 – an increase of 21.18% over the previous week. Adverum Biotechnologies employs 155 staff and has a trailing 12-month revenue of around $1 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Latest market close | $3.49 |
---|---|
52-week range | $2.64 - $10.84 |
50-day moving average | $4.05 |
200-day moving average | $5.85 |
Wall St. target price | $26.00 |
PE ratio | N/A |
Dividend yield | N/A |
Earnings per share (TTM) | $-6.62 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.49 from 2025-05-02
1 week (2025-04-24) | 17.51% |
---|---|
1 month (2025-04-04) | -9.59% |
3 months (2025-02-05) | -22.79% |
6 months (2024-11-05) | -54.79% |
1 year (2024-05-03) | -66.54% |
---|---|
2 years (2023-05-04) | -55.50% |
3 years (2022-05-04) | 11.5 |
5 years (2020-05-04) | 137.3 |
Revenue TTM | $1 million |
---|---|
Gross profit TTM | $-76,041,000 |
Return on assets TTM | -51.83% |
Return on equity TTM | -189.84% |
Profit margin | 0% |
Book value | $3.39 |
Market Capitalization | $68.1 million |
TTM: trailing 12 months
We're not expecting Adverum Biotechnologies to pay a dividend over the next 12 months.
Adverum Biotechnologies's shares were split on a 1:10 basis on 20 March 2024 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Adverum Biotechnologies shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Adverum Biotechnologies shares which in turn could have impacted Adverum Biotechnologies's share price.
Over the last 12 months, Adverum Biotechnologies's shares have ranged in value from as little as $2.64 up to $10.84. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Adverum Biotechnologies's is 1.091. This would suggest that Adverum Biotechnologies's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Adverum Biotechnologies, Inc. , a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing BGTF-027 (AAV. 7m8-L-opsin), a novel gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Ray Therapeutics; Lexeo Therapeutics; and Virovek, Inc.
Track the progress of the S&P 500 stocks to make more informed investment decisions.
See our picks for the best brokers for trading S&P 500 stocks, ETFs, options and futures.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
Stock lending allows investors to loan out their existing stocks, although it has both advantages and disadvantages.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Some of the best trading apps like Robinhood are SoFi, Tastytrade, Public, eToro, Acorns, Interactive Brokers, E*TRADE and more.
SoFi Invest is a no-fee commissions platform with both active and automated investment accounts.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.